variou
defens
mechan
evolv
respiratori
tract
prevent
control
infect
advanc
pathomechan
involv
carv
infect
made
recent
excess
inflamm
associ
sever
infect
control
block
costimulatori
signal
without
alter
immunemedi
viru
clearanc
recent
studi
suggest
activ
effector
cell
virusinfect
lung
gener
inflammatori
cell
local
modif
immun
respons
infect
epithelium
may
lead
viru
clearanc
regul
acut
inflamm
possibl
immunolog
memori
resolut
respiratori
viru
infect
requir
elimin
viru
also
repair
regener
normal
lung
structur
restor
normal
pulmonari
function
cell
molecul
regul
process
epitheli
cell
mesenchym
cell
transit
well
transform
fibroblast
fibrocyt
myofibroblast
dysregul
process
respons
lung
inflamm
associ
progress
pulmonari
injuri
lung
fibrosi
ltx
recipi
carv
infect
may
caus
inflammatori
process
mediat
innat
adapt
immun
respons
result
injuri
airway
epitheli
cell
subepitheli
structur
lead
obliter
small
airway
apart
direct
sequela
carv
may
promot
immunolog
mediat
lung
injuri
result
develop
acut
reject
ar
clinic
term
chronic
lung
allograft
dysfunct
clad
bronchiol
obliteran
syndrom
bo
clinic
pictur
irrevers
declin
forc
expiratori
volum
second
fev
histopatholog
obliter
termin
bronchioli
fibromyxomat
tissu
recogn
bo
import
prognosi
limit
factor
follow
ltx
remain
major
impedi
longterm
graft
patient
surviv
ltx
averag
affect
everi
second
recipi
year
annual
incid
bo
ltx
bo
progress
diseas
bo
patient
die
respiratori
failur
surviv
affect
patient
ltx
recipi
symptom
carv
infect
may
resembl
clinic
problem
like
caus
infect
bacteri
fungal
acut
reject
drug
toxic
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
also
caus
commun
outbreak
share
similar
clinic
featur
may
present
diagnost
difficulti
contrast
nonimmunosuppress
host
carv
infect
usual
lead
sever
ill
lung
transplant
recipi
higher
incid
respiratori
failur
recent
clinic
trial
rsvinfect
ltx
patient
median
declin
fev
compar
preinfect
level
seventyfour
percent
patient
symptom
lower
respiratori
tract
infect
signific
infiltr
chest
xray
retrospect
singlecent
studi
time
span
ltx
patient
present
carv
infect
coxsacki
rv
pv
cov
rsv
hmpv
flu
demonstr
pulmonari
infiltr
asymptomat
acut
consequ
rsv
infect
includ
bronchiol
pneumonia
respiratori
failur
perman
longterm
effect
follow
ltx
includ
develop
new
progress
chronic
allograft
dysfunct
manifest
clinic
bo
rhinovir
infect
persist
lung
transplant
recipi
graft
dysfunct
tempor
associ
observ
carv
infect
ar
cumul
infect
rate
carv
lung
transplant
recipi
earlier
retrospect
singlecent
studi
year
rang
retrospect
studi
test
virus
newli
recogn
import
pathogen
bo
especi
hmpv
therefor
apart
methodolog
issu
bo
incid
may
exactli
estim
studi
sever
publish
prospect
studi
use
polymeras
chain
reaction
pcr
techniqu
carv
ltx
involv
patient
surveil
period
month
symptom
respiratori
tract
infect
rti
frequent
screen
patient
incid
carv
variabl
differ
incid
explain
differ
methodolog
inclus
criteria
swiss
studi
patient
underw
bronchoscopi
studi
make
difficult
calcul
true
incid
respiratori
viral
infect
compar
uninfect
patient
canadian
studi
stabl
patient
includ
screen
carv
match
uninfect
patient
exclud
estim
true
incid
carv
observ
period
us
studi
ltx
recipi
contact
weekli
telephon
screen
symptom
symptom
rti
therefor
frequent
serolog
identifi
carv
studi
hmpv
investig
pv
domin
pathogen
german
surveil
studi
use
pcr
test
upper
respiratori
sampl
antigen
test
sampl
lower
respiratori
tract
follow
rsv
prospect
studi
german
surveil
studi
annual
incid
carvposit
recipi
describ
higher
prospect
studi
use
pcr
techniqu
summari
prospect
studi
describ
incid
case
per
patientyear
tabl
infect
ltx
recipi
earli
studi
present
respiratori
failur
interestingli
retrospect
studi
bo
incid
carvposit
lung
transplant
recipi
much
common
year
prospect
studi
versu
sever
surveil
retrospect
studi
confirm
associ
carv
infect
well
carv
onset
bo
studi
heterogen
limit
design
case
select
diagnost
procedur
associ
identifi
mainli
paramyxovirus
associ
influenza
av
less
well
document
accord
publish
literatur
incid
bo
ltx
recipi
infect
carv
follow
month
patient
may
present
onset
clad
immedi
carv
infect
later
initi
recoveri
fev
viral
infect
lack
inform
potenti
role
virus
difficult
grow
rv
human
cov
enterovirus
hmpv
recent
recogn
import
pathogen
ltx
viru
isol
still
gold
standard
laboratori
detect
respiratori
virus
howev
viru
isol
cell
cultur
slow
alway
technic
success
therefor
method
longer
use
transplant
set
rapid
workup
crucial
rapid
antigen
detect
test
antibodi
immunofluoresc
test
ift
avail
carv
detect
viral
antigen
report
less
sensit
less
specif
cell
cultur
allow
rapid
detect
nucleic
acid
amplif
test
carv
pcr
rapid
sensit
commerci
avail
singl
multiplex
format
signific
viru
detect
pcr
asymptomat
patient
unknown
viru
detect
pcr
may
reflect
activ
infect
serolog
play
role
detect
carv
infect
ltx
upper
respiratori
sampl
swab
no
use
combin
pcr
techniqu
avoid
need
bronchoscopi
special
swab
sampl
use
mouth
rins
accept
altern
ltx
recipi
bronchoalveolar
lavag
bal
widespread
diagnost
tool
given
broad
spectrum
possibl
diagnosi
ltx
patient
symptom
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
bronchoscopi
bal
advis
circumst
bal
sensit
detect
carv
surveil
studi
recent
random
control
trial
rct
rsv
infect
detect
pcr
potenti
incid
bo
untreat
carv
infect
threat
respiratori
failur
infect
ltx
recipi
illustr
need
effect
treatment
carv
infect
unfortun
respiratori
virus
hard
target
variou
reason
time
viru
spend
host
insid
host
cell
viru
protect
host
immun
system
well
avail
circul
enzym
limit
number
potenti
drug
target
sinc
virus
use
host
biochem
mechan
multipli
virus
multipli
quickli
antivir
drug
often
littl
effect
time
symptom
appear
addit
resist
commonli
use
antivir
develop
earli
theoret
virus
target
inhibit
stage
viral
attach
intern
fusion
uncoat
replic
assembl
releas
unfortun
except
neuraminidas
inhibitor
influenza
regist
drug
avail
treatment
carv
infect
adult
treatment
strategi
may
symptomat
case
usual
consist
steroid
oxygen
antibiot
case
concomit
bacteri
infect
ribavirin
known
sinc
regist
use
chronic
hepat
c
viru
infect
ribavirin
purin
nucleosid
analogu
efficaci
mani
rna
virus
includ
rsv
hmpv
pv
repres
viabl
treatment
option
pv
infect
ribavirin
shown
vitro
activ
rsv
aerosol
form
approv
treatment
lower
respiratori
tract
diseas
due
rsv
certain
atrisk
popul
data
intraven
use
ribavirin
remain
limit
ltx
recipi
drawback
inhal
ribavirin
includ
difficulti
administr
requir
continu
inhal
along
associ
risk
bronchoconstrict
respiratori
distress
may
necessit
discontinu
addit
aerosol
ribavirin
consid
potenti
hazard
teratogen
environ
includ
health
care
worker
well
excess
expens
consid
limit
widespread
accept
nebul
administr
miss
sever
center
use
oral
ribavirin
offlabel
altern
treatment
paramyxoviru
infect
ltx
retrospect
studi
demonstr
signific
differ
outcom
oral
inhal
ribavirin
therapi
rsv
infect
ltx
recent
multicent
trial
involv
rsvinfect
patient
site
australia
austria
germani
franc
canada
unit
state
inhal
ribavirin
use
infect
individu
oral
ribavirin
intraven
ribavirin
intraven
immunoglobulin
ivig
puls
steroid
palivizumab
optim
durat
ribavirin
therapi
unknown
although
treatment
oral
day
led
viru
elimin
patient
retrospect
studi
particular
note
ribavirin
contraind
pvinfect
recipi
studi
termin
earli
anoth
quarter
case
due
advers
effect
twiceweekli
monitor
blood
cell
count
risk
hemolyt
anemia
renal
function
mandatori
ribavirin
therapi
compar
patient
popul
treat
ribavirin
frequent
discontinu
due
toxic
necessari
ltx
popul
like
explan
remain
combin
toxic
ribavirin
inher
mainten
medic
requir
ltx
distinct
must
made
short
longterm
effect
treatment
ribavirin
prior
studi
focus
shortterm
effect
ribavirin
treatment
surviv
acut
phase
shorter
hospit
length
stay
found
benefici
effect
retrospect
singlecent
studi
suggest
ltx
patient
treat
ribavirin
better
pulmonari
function
month
paramyxoviru
infect
found
oral
ribavirin
reduc
number
complic
cours
paramyxoviru
infect
reduc
longterm
risk
bo
recoveri
pulmonari
function
postinfect
significantli
better
ribavirintr
patient
n
patient
treat
support
care
n
retrospect
studi
patient
treat
oral
ribavirin
lower
incid
bo
ribavirin
group
versu
nonribavirin
group
p
within
month
latter
subgroup
treat
support
care
studi
contraind
ribavirin
eg
advanc
kidney
diseas
anemia
ribavirin
studi
ltx
lack
random
placebocontrol
design
make
unsuit
make
evidencebas
recommend
clearli
need
rct
determin
efficaci
oral
ribavirin
sinc
unnecessari
treatment
drug
alway
avoid
ribavirin
unfavor
side
effect
firm
conclus
need
clinic
benefit
treatment
oral
ribavirin
seem
promis
inexpens
therapi
may
signific
impact
longterm
morbid
mortal
lung
transplant
recipi
anecdot
case
report
offlabel
use
pavilizumab
ivig
rsvinfect
ltx
recipi
sever
agent
studi
influenza
includ
fludas
nitazoxanid
data
publish
ltx
patient
rna
interfer
natur
biolog
process
wherebi
small
interf
rna
sirna
direct
sequencespecif
degrad
mrna
lead
reduc
express
correspond
protein
sirna
target
rsv
nucleocapsid
messeng
rna
prevent
format
nucleocapsid
protein
therebi
reduc
viral
replic
intranas
administr
significantli
inhibit
rate
rsv
infect
phase
experiment
infect
studi
healthi
adult
pivot
studi
rsvinfect
ltx
patient
nebul
treatment
prove
safe
welltoler
incid
new
progress
bo
decreas
day
patient
treat
compar
placebo
efficaci
administr
addit
standard
care
prevent
new
progress
bo
rsvinfect
ltx
patient
evalu
larg
random
doubleblind
placebocontrol
trial
phase
trial
subject
random
receiv
aerosol
placebo
daili
day
found
safe
well
toler
day
patient
n
compar
placebo
n
trend
toward
decreas
new
progress
bo
vs
p
signific
perprotocol
cohort
p
treatment
effect
enhanc
start
day
symptom
onset
effect
independ
ribavirin
treatment
presatovir
oral
rsv
fusion
inhibitor
potent
select
antirsv
activ
vitro
phase
random
doubleblind
placebocontrol
studi
conduct
evalu
safeti
toler
efficaci
presatovir
healthi
adult
volunt
infect
rsv
challeng
viru
treatment
presatovir
result
lower
mean
area
curv
auc
viral
load
initi
dose
end
quarantin
viral
load
assess
twice
daili
use
nasal
wash
total
symptom
score
entir
quarantin
period
result
phase
rct
evalu
effect
ltx
recipi
rsv
infect
expect
soon
sever
unmet
need
develop
effect
therapi
carv
one
wider
treatment
window
agent
report
less
effect
patient
present
hour
symptom
onset
therapi
costeffect
reduc
threat
resist
continu
antigen
drift
antigen
shift
virus
altern
formul
eg
intraven
drug
hospit
patient
avail
well
drug
sever
ill
hospit
patient
pediatr
patient
prevent
carv
infect
utmost
import
ltx
annual
influenza
vaccin
strongli
recommend
lung
transplant
recipi
includ
household
member
wear
face
mask
avoid
contact
infect
person
skin
disinfect
usual
recommend
prevent
measur
ltx
recipi
although
systemat
evalu
highrisk
cohort
